Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 9 studies | 39% ± 20% | |
endothelial cell | 8 studies | 24% ± 12% | |
fibroblast | 7 studies | 24% ± 6% | |
regulatory T cell | 7 studies | 18% ± 3% | |
CD4-positive, alpha-beta T cell | 6 studies | 22% ± 4% | |
connective tissue cell | 6 studies | 41% ± 18% | |
neuron | 6 studies | 59% ± 27% | |
hematopoietic precursor cell | 5 studies | 34% ± 11% | |
myofibroblast cell | 5 studies | 27% ± 7% | |
abnormal cell | 5 studies | 34% ± 13% | |
pericyte | 5 studies | 28% ± 5% | |
smooth muscle cell | 5 studies | 27% ± 6% | |
erythroblast | 5 studies | 45% ± 23% | |
basal cell | 5 studies | 34% ± 18% | |
ciliated cell | 5 studies | 32% ± 11% | |
CD8-positive, alpha-beta T cell | 5 studies | 21% ± 3% | |
conventional dendritic cell | 4 studies | 30% ± 8% | |
progenitor cell | 4 studies | 39% ± 9% | |
mesothelial cell | 4 studies | 38% ± 13% | |
pro-B cell | 4 studies | 27% ± 4% | |
megakaryocyte-erythroid progenitor cell | 4 studies | 45% ± 21% | |
plasmablast | 3 studies | 45% ± 11% | |
neural crest cell | 3 studies | 39% ± 15% | |
club cell | 3 studies | 20% ± 5% | |
B cell | 3 studies | 22% ± 6% | |
dendritic cell | 3 studies | 30% ± 10% | |
intestinal crypt stem cell | 3 studies | 22% ± 3% | |
erythrocyte | 3 studies | 41% ± 15% | |
natural killer cell | 3 studies | 20% ± 5% | |
hematopoietic stem cell | 3 studies | 27% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 100% | 493.96 | 180 / 180 | 100% | 91.28 | 429 / 430 |
brain | 100% | 1022.78 | 2641 / 2642 | 100% | 72.54 | 702 / 705 |
uterus | 99% | 435.74 | 168 / 170 | 99% | 120.34 | 456 / 459 |
intestine | 98% | 384.70 | 950 / 966 | 98% | 82.83 | 519 / 527 |
skin | 98% | 358.95 | 1769 / 1809 | 98% | 70.73 | 461 / 472 |
prostate | 97% | 496.38 | 238 / 245 | 98% | 55.66 | 493 / 502 |
stomach | 96% | 355.73 | 345 / 359 | 98% | 71.41 | 279 / 286 |
bladder | 95% | 332.00 | 20 / 21 | 98% | 117.18 | 495 / 504 |
pancreas | 98% | 304.66 | 322 / 328 | 95% | 48.66 | 169 / 178 |
thymus | 98% | 304.42 | 639 / 653 | 95% | 48.04 | 573 / 605 |
breast | 91% | 382.25 | 418 / 459 | 99% | 118.37 | 1105 / 1118 |
lung | 93% | 283.15 | 537 / 578 | 95% | 61.02 | 1100 / 1155 |
esophagus | 86% | 380.94 | 1238 / 1445 | 97% | 45.10 | 178 / 183 |
adrenal gland | 100% | 661.83 | 258 / 258 | 81% | 29.84 | 187 / 230 |
kidney | 100% | 523.15 | 89 / 89 | 61% | 21.02 | 553 / 901 |
liver | 61% | 107.50 | 138 / 226 | 54% | 29.07 | 218 / 406 |
eye | 0% | 0 | 0 / 0 | 100% | 61.79 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 55.87 | 29 / 29 |
spleen | 100% | 474.20 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 87.56 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 138.10 | 1 / 1 |
peripheral blood | 93% | 371.21 | 867 / 929 | 0% | 0 | 0 / 0 |
adipose | 86% | 191.58 | 1035 / 1204 | 0% | 0 | 0 / 0 |
muscle | 61% | 107.70 | 492 / 803 | 0% | 0 | 0 / 0 |
heart | 28% | 41.43 | 243 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 24% | 40.74 | 322 / 1335 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0007283 | Biological process | spermatogenesis |
GO_0006629 | Biological process | lipid metabolic process |
GO_0007399 | Biological process | nervous system development |
GO_0016042 | Biological process | lipid catabolic process |
GO_0008247 | Cellular component | 1-alkyl-2-acetylglycerophosphocholine esterase complex |
GO_0005829 | Cellular component | cytosol |
GO_0016020 | Cellular component | membrane |
GO_0005737 | Cellular component | cytoplasm |
GO_0044877 | Molecular function | protein-containing complex binding |
GO_0046982 | Molecular function | protein heterodimerization activity |
GO_0003847 | Molecular function | 1-alkyl-2-acetylglycerophosphocholine esterase activity |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0047179 | Molecular function | platelet-activating factor acetyltransferase activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0005515 | Molecular function | protein binding |
Gene name | PAFAH1B3 |
Protein name | Platelet-activating factor acetylhydrolase IB subunit alpha1 (EC 3.1.1.47) (PAF acetylhydrolase 29 kDa subunit) (PAF-AH 29 kDa subunit) (PAF-AH subunit gamma) (PAFAH subunit gamma) Platelet activating factor acetylhydrolase 1b catalytic subunit 3 1-alkyl-2-acetylglycerophosphocholine esterase (EC 3.1.1.47) |
Synonyms | PAFAHG |
Description | FUNCTION: Alpha1 catalytic subunit of the cytosolic type I platelet-activating factor (PAF) acetylhydrolase (PAF-AH (I)) heterotetrameric enzyme that catalyzes the hydrolyze of the acetyl group at the sn-2 position of PAF and its analogs and modulates the action of PAF. The activity and substrate specificity of PAF-AH (I) are affected by its subunit composition. Both alpha1/alpha1 homodimer (PAFAH1B3/PAFAH1B3 homodimer) and alpha1/alpha2 heterodimer(PAFAH1B3/PAFAH1B2 heterodimer) hydrolyze 1-O-alkyl-2-acetyl-sn-glycero-3-phosphoric acid (AAGPA) more efficiently than PAF, but they have little hydrolytic activity towards 1-O-alkyl-2-acetyl-sn-glycero-3-phosphorylethanolamine (AAGPE). Plays an important role during the development of brain. . |
Accessions | M0R1K3 ENST00000594989.5 M0QZT2 M0R323 M0R389 ENST00000595530.5 ENST00000262890.8 Q15102 ENST00000538771.5 ENST00000599778.1 M0QXS6 ENST00000596265.5 ENST00000601865.5 |